Floatz logo

Gemtuzumab Ozogamicin

Myelodysplastic Syndrome With Excess Blasts

M.D. Anderson Cancer Centerantibody_drug_conjugatePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

32 Active assets in the Myelodysplastic Syndrome With Excess Blasts cohort.

Asset / SponsorPhaseRating
Cytosin-Arabinosid
University of Southern California
Phase 3BBB
Fludarabine
Fred Hutchinson Cancer Center
Phase 3BB
TACROLIMUS
Fred Hutchinson Cancer Center
Phase 2BB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2BB
ETOPOSIDE
M.D. Anderson Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

Gemtuzumab Ozogamicin is also rated in:

leukemiaDormant
BB
Indicative ·
69 / 100
View asset →
acute myeloid leukemiaDormant
BB
Indicative ·
67 / 100
View asset →
myelodysplastic syndromeDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →